nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—PTGS2—bone cancer	0.446	1	CbGaD
Etodolac—UGT2B7—Epirubicin—bone cancer	0.181	0.521	CbGbCtD
Etodolac—PTGS2—Cisplatin—bone cancer	0.0747	0.215	CbGbCtD
Etodolac—SLC22A6—Methotrexate—bone cancer	0.0359	0.103	CbGbCtD
Etodolac—ALB—Methotrexate—bone cancer	0.0306	0.0879	CbGbCtD
Etodolac—CYP2C9—Cisplatin—bone cancer	0.0254	0.073	CbGbCtD
Etodolac—UGT1A10—Irinotecan Pathway—CYP3A4—bone cancer	0.00545	0.071	CbGpPWpGaD
Etodolac—UGT1A10—Tamoxifen metabolism—CYP3A4—bone cancer	0.00394	0.0514	CbGpPWpGaD
Etodolac—UGT1A10—Metapathway biotransformation—CYP4V2—bone cancer	0.00365	0.0476	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.00342	0.0446	CbGpPWpGaD
Etodolac—UGT2B7—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00289	0.0376	CbGpPWpGaD
Etodolac—RXRA—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00225	0.0294	CbGpPWpGaD
Etodolac—UGT1A3—Estrogen metabolism—CYP3A4—bone cancer	0.00177	0.0231	CbGpPWpGaD
Etodolac—UGT2B7—Estrogen metabolism—CYP3A4—bone cancer	0.00151	0.0197	CbGpPWpGaD
Etodolac—UGT1A9—Irinotecan Pathway—CYP3A4—bone cancer	0.0015	0.0195	CbGpPWpGaD
Etodolac—UGT1A3—Metapathway biotransformation—CYP4V2—bone cancer	0.00145	0.019	CbGpPWpGaD
Etodolac—RXRA—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00135	0.0176	CbGpPWpGaD
Etodolac—UGT2B7—Tamoxifen metabolism—CYP3A4—bone cancer	0.00133	0.0174	CbGpPWpGaD
Etodolac—RXRA—Nuclear Receptors—NR1I2—bone cancer	0.00132	0.0173	CbGpPWpGaD
Etodolac—UGT2B7—Metapathway biotransformation—CYP4V2—bone cancer	0.00124	0.0161	CbGpPWpGaD
Etodolac—UGT1A9—Estrogen metabolism—CYP3A4—bone cancer	0.00123	0.016	CbGpPWpGaD
Etodolac—UGT1A3—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00112	0.0146	CbGpPWpGaD
Etodolac—RXRA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00105	0.0136	CbGpPWpGaD
Etodolac—UGT1A9—Metapathway biotransformation—CYP4V2—bone cancer	0.001	0.0131	CbGpPWpGaD
Etodolac—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.001	0.013	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—FOLR1—bone cancer	0.000976	0.0127	CbGpPWpGaD
Etodolac—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000956	0.0125	CbGpPWpGaD
Etodolac—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.000919	0.012	CbGpPWpGaD
Etodolac—RXRA—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000888	0.0116	CbGpPWpGaD
Etodolac—UGT1A9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000774	0.0101	CbGpPWpGaD
Etodolac—RXRA—Orphan transporters—TUBB4B—bone cancer	0.000726	0.00947	CbGpPWpGaD
Etodolac—UGT1A10—Metapathway biotransformation—CYP3A4—bone cancer	0.000722	0.00942	CbGpPWpGaD
Etodolac—RXRA—PPAR Alpha Pathway—CDK4—bone cancer	0.00065	0.00847	CbGpPWpGaD
Etodolac—RXRA—Orphan transporters—TUBB2A—bone cancer	0.000627	0.00817	CbGpPWpGaD
Etodolac—UGT1A10—Metapathway biotransformation—GSTP1—bone cancer	0.000618	0.00805	CbGpPWpGaD
Etodolac—UGT1A9—PPAR Alpha Pathway—CDK4—bone cancer	0.000566	0.00738	CbGpPWpGaD
Etodolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000542	0.00706	CbGpPWpGaD
Etodolac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000541	0.00706	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000541	0.00705	CbGpPWpGaD
Etodolac—RXRA—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000537	0.007	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—ZNF77—bone cancer	0.000534	0.00696	CbGpPWpGaD
Etodolac—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000483	0.00629	CbGpPWpGaD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000478	0.00623	CbGpPWpGaD
Etodolac—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000464	0.00605	CbGpPWpGaD
Etodolac—RXRA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000435	0.00568	CbGpPWpGaD
Etodolac—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000431	0.00561	CbGpPWpGaD
Etodolac—UGT1A3—Phase II conjugation—GSTP1—bone cancer	0.000426	0.00556	CbGpPWpGaD
Etodolac—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000424	0.00553	CbGpPWpGaD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.000419	0.00546	CbGpPWpGaD
Etodolac—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000401	0.00522	CbGpPWpGaD
Etodolac—UGT2B7—Phase II conjugation—GSTP1—bone cancer	0.000362	0.00473	CbGpPWpGaD
Etodolac—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000352	0.00459	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.00035	0.00457	CbGpPWpGaD
Etodolac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000348	0.00454	CbGpPWpGaD
Etodolac—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000335	0.00436	CbGpPWpGaD
Etodolac—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000331	0.00432	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000316	0.00412	CbGpPWpGaD
Etodolac—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000309	0.00403	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000302	0.00393	CbGpPWpGaD
Etodolac—UGT1A9—Phase II conjugation—GSTP1—bone cancer	0.000295	0.00384	CbGpPWpGaD
Etodolac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000294	0.00384	CbGpPWpGaD
Etodolac—UGT1A3—Biological oxidations—CYP3A4—bone cancer	0.000292	0.0038	CbGpPWpGaD
Etodolac—UGT1A3—Metapathway biotransformation—CYP3A4—bone cancer	0.000288	0.00375	CbGpPWpGaD
Etodolac—UGT1A3—NRF2 pathway—TGFBR2—bone cancer	0.000284	0.00371	CbGpPWpGaD
Etodolac—UGT1A3—NRF2 pathway—GSTP1—bone cancer	0.000284	0.00371	CbGpPWpGaD
Etodolac—Paraesthesia—Cisplatin—bone cancer	0.000275	0.00211	CcSEcCtD
Etodolac—Eosinophilia—Epirubicin—bone cancer	0.000274	0.00211	CcSEcCtD
Etodolac—Dyspnoea—Cisplatin—bone cancer	0.000273	0.0021	CcSEcCtD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000273	0.00356	CbGpPWpGaD
Etodolac—RXRA—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000273	0.00355	CbGpPWpGaD
Etodolac—Pancreatitis—Epirubicin—bone cancer	0.000271	0.00208	CcSEcCtD
Etodolac—Abdominal pain upper—Doxorubicin—bone cancer	0.000271	0.00208	CcSEcCtD
Etodolac—Photosensitivity reaction—Methotrexate—bone cancer	0.00027	0.00207	CcSEcCtD
Etodolac—ALB—Folate Metabolism—DHFR—bone cancer	0.000268	0.00349	CbGpPWpGaD
Etodolac—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000267	0.00205	CcSEcCtD
Etodolac—Decreased appetite—Cisplatin—bone cancer	0.000266	0.00205	CcSEcCtD
Etodolac—Bronchitis—Epirubicin—bone cancer	0.000266	0.00204	CcSEcCtD
Etodolac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000265	0.00346	CbGpPWpGaD
Etodolac—Pneumonia—Methotrexate—bone cancer	0.000265	0.00204	CcSEcCtD
Etodolac—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000263	0.00343	CbGpPWpGaD
Etodolac—Pancytopenia—Epirubicin—bone cancer	0.000263	0.00202	CcSEcCtD
Etodolac—Gastritis—Doxorubicin—bone cancer	0.000262	0.00201	CcSEcCtD
Etodolac—Pain—Cisplatin—bone cancer	0.000262	0.00201	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000261	0.00201	CcSEcCtD
Etodolac—Renal failure—Methotrexate—bone cancer	0.000259	0.00199	CcSEcCtD
Etodolac—Neutropenia—Epirubicin—bone cancer	0.000259	0.00199	CcSEcCtD
Etodolac—Dysuria—Epirubicin—bone cancer	0.000259	0.00199	CcSEcCtD
Etodolac—Abdominal distension—Doxorubicin—bone cancer	0.000258	0.00198	CcSEcCtD
Etodolac—RXRA—Gene Expression—ZNF77—bone cancer	0.000257	0.00335	CbGpPWpGaD
Etodolac—Stomatitis—Methotrexate—bone cancer	0.000257	0.00197	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000256	0.00334	CbGpPWpGaD
Etodolac—Conjunctivitis—Methotrexate—bone cancer	0.000256	0.00197	CcSEcCtD
Etodolac—Asthma—Doxorubicin—bone cancer	0.000256	0.00197	CcSEcCtD
Etodolac—Pollakiuria—Epirubicin—bone cancer	0.000256	0.00196	CcSEcCtD
Etodolac—Eosinophilia—Doxorubicin—bone cancer	0.000254	0.00195	CcSEcCtD
Etodolac—Sweating—Methotrexate—bone cancer	0.000253	0.00194	CcSEcCtD
Etodolac—Photosensitivity reaction—Epirubicin—bone cancer	0.000253	0.00194	CcSEcCtD
Etodolac—Feeling abnormal—Cisplatin—bone cancer	0.000253	0.00194	CcSEcCtD
Etodolac—Haematuria—Methotrexate—bone cancer	0.000251	0.00193	CcSEcCtD
Etodolac—Pancreatitis—Doxorubicin—bone cancer	0.000251	0.00193	CcSEcCtD
Etodolac—Hyperglycaemia—Epirubicin—bone cancer	0.00025	0.00192	CcSEcCtD
Etodolac—UGT1A3—Biological oxidations—GSTP1—bone cancer	0.000249	0.00325	CbGpPWpGaD
Etodolac—Pneumonia—Epirubicin—bone cancer	0.000248	0.00191	CcSEcCtD
Etodolac—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.000248	0.00323	CbGpPWpGaD
Etodolac—Bronchitis—Doxorubicin—bone cancer	0.000246	0.00189	CcSEcCtD
Etodolac—Agranulocytosis—Methotrexate—bone cancer	0.000246	0.00189	CcSEcCtD
Etodolac—UGT1A3—Metapathway biotransformation—GSTP1—bone cancer	0.000246	0.00321	CbGpPWpGaD
Etodolac—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000245	0.00188	CcSEcCtD
Etodolac—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000245	0.00319	CbGpPWpGaD
Etodolac—Pancytopenia—Doxorubicin—bone cancer	0.000243	0.00187	CcSEcCtD
Etodolac—Renal failure—Epirubicin—bone cancer	0.000243	0.00186	CcSEcCtD
Etodolac—Body temperature increased—Cisplatin—bone cancer	0.000242	0.00186	CcSEcCtD
Etodolac—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000242	0.00315	CbGpPWpGaD
Etodolac—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000242	0.00315	CbGpPWpGaD
Etodolac—Jaundice—Epirubicin—bone cancer	0.000241	0.00185	CcSEcCtD
Etodolac—Stomatitis—Epirubicin—bone cancer	0.000241	0.00185	CcSEcCtD
Etodolac—Conjunctivitis—Epirubicin—bone cancer	0.00024	0.00184	CcSEcCtD
Etodolac—Neutropenia—Doxorubicin—bone cancer	0.000239	0.00184	CcSEcCtD
Etodolac—Dysuria—Doxorubicin—bone cancer	0.000239	0.00184	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—bone cancer	0.000238	0.00183	CcSEcCtD
Etodolac—RXRA—Regulation of Androgen receptor activity—JUN—bone cancer	0.000237	0.00309	CbGpPWpGaD
Etodolac—Hepatitis—Methotrexate—bone cancer	0.000237	0.00182	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—bone cancer	0.000237	0.00182	CcSEcCtD
Etodolac—Sweating—Epirubicin—bone cancer	0.000237	0.00182	CcSEcCtD
Etodolac—Pollakiuria—Doxorubicin—bone cancer	0.000237	0.00182	CcSEcCtD
Etodolac—Haematuria—Epirubicin—bone cancer	0.000235	0.00181	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—bone cancer	0.000235	0.0018	CcSEcCtD
Etodolac—ALB—Platelet degranulation—SPARC—bone cancer	0.000235	0.00306	CbGpPWpGaD
Etodolac—Photosensitivity reaction—Doxorubicin—bone cancer	0.000234	0.0018	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000234	0.00304	CbGpPWpGaD
Etodolac—Sinusitis—Epirubicin—bone cancer	0.000231	0.00178	CcSEcCtD
Etodolac—RXRA—Biological oxidations—CYP3A4—bone cancer	0.000231	0.00301	CbGpPWpGaD
Etodolac—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000231	0.00301	CbGpPWpGaD
Etodolac—Hyperglycaemia—Doxorubicin—bone cancer	0.000231	0.00177	CcSEcCtD
Etodolac—Agranulocytosis—Epirubicin—bone cancer	0.00023	0.00177	CcSEcCtD
Etodolac—Pneumonia—Doxorubicin—bone cancer	0.00023	0.00176	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—bone cancer	0.000228	0.00175	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000226	0.00174	CcSEcCtD
Etodolac—Hypersensitivity—Cisplatin—bone cancer	0.000226	0.00173	CcSEcCtD
Etodolac—RXRA—NRF2 pathway—GSTP1—bone cancer	0.000225	0.00294	CbGpPWpGaD
Etodolac—RXRA—NRF2 pathway—TGFBR2—bone cancer	0.000225	0.00294	CbGpPWpGaD
Etodolac—Renal failure—Doxorubicin—bone cancer	0.000224	0.00172	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—bone cancer	0.000224	0.00172	CcSEcCtD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000224	0.00291	CbGpPWpGaD
Etodolac—Haemoglobin—Epirubicin—bone cancer	0.000223	0.00171	CcSEcCtD
Etodolac—Stomatitis—Doxorubicin—bone cancer	0.000223	0.00171	CcSEcCtD
Etodolac—Jaundice—Doxorubicin—bone cancer	0.000223	0.00171	CcSEcCtD
Etodolac—Rhinitis—Epirubicin—bone cancer	0.000222	0.00171	CcSEcCtD
Etodolac—Conjunctivitis—Doxorubicin—bone cancer	0.000222	0.00171	CcSEcCtD
Etodolac—Hepatitis—Epirubicin—bone cancer	0.000221	0.0017	CcSEcCtD
Etodolac—Haemorrhage—Epirubicin—bone cancer	0.000221	0.0017	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—bone cancer	0.000221	0.0017	CcSEcCtD
Etodolac—Asthenia—Cisplatin—bone cancer	0.00022	0.00169	CcSEcCtD
Etodolac—Pharyngitis—Epirubicin—bone cancer	0.00022	0.00169	CcSEcCtD
Etodolac—Sweating—Doxorubicin—bone cancer	0.000219	0.00168	CcSEcCtD
Etodolac—Haematuria—Doxorubicin—bone cancer	0.000218	0.00167	CcSEcCtD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000217	0.00283	CbGpPWpGaD
Etodolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000216	0.00282	CbGpPWpGaD
Etodolac—Sinusitis—Doxorubicin—bone cancer	0.000214	0.00165	CcSEcCtD
Etodolac—Visual impairment—Epirubicin—bone cancer	0.000213	0.00164	CcSEcCtD
Etodolac—Agranulocytosis—Doxorubicin—bone cancer	0.000213	0.00164	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000213	0.00277	CbGpPWpGaD
Etodolac—Chills—Methotrexate—bone cancer	0.000212	0.00163	CcSEcCtD
Etodolac—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000212	0.00277	CbGpPWpGaD
Etodolac—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000212	0.00276	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00021	0.00273	CbGpPWpGaD
Etodolac—Diarrhoea—Cisplatin—bone cancer	0.00021	0.00161	CcSEcCtD
Etodolac—Erythema multiforme—Epirubicin—bone cancer	0.000209	0.00161	CcSEcCtD
Etodolac—Alopecia—Methotrexate—bone cancer	0.000209	0.00161	CcSEcCtD
Etodolac—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000209	0.00273	CbGpPWpGaD
Etodolac—Tinnitus—Epirubicin—bone cancer	0.000207	0.00159	CcSEcCtD
Etodolac—Haemoglobin—Doxorubicin—bone cancer	0.000206	0.00158	CcSEcCtD
Etodolac—Flushing—Epirubicin—bone cancer	0.000206	0.00158	CcSEcCtD
Etodolac—Rhinitis—Doxorubicin—bone cancer	0.000205	0.00158	CcSEcCtD
Etodolac—Hepatitis—Doxorubicin—bone cancer	0.000205	0.00157	CcSEcCtD
Etodolac—Haemorrhage—Doxorubicin—bone cancer	0.000205	0.00157	CcSEcCtD
Etodolac—Pharyngitis—Doxorubicin—bone cancer	0.000203	0.00156	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000202	0.00263	CbGpPWpGaD
Etodolac—Dysgeusia—Methotrexate—bone cancer	0.000202	0.00155	CcSEcCtD
Etodolac—UGT1A9—Biological oxidations—CYP3A4—bone cancer	0.000201	0.00263	CbGpPWpGaD
Etodolac—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0002	0.00261	CbGpPWpGaD
Etodolac—Chills—Epirubicin—bone cancer	0.000199	0.00153	CcSEcCtD
Etodolac—UGT1A9—Metapathway biotransformation—CYP3A4—bone cancer	0.000199	0.00259	CbGpPWpGaD
Etodolac—Arrhythmia—Epirubicin—bone cancer	0.000198	0.00152	CcSEcCtD
Etodolac—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000198	0.00258	CbGpPWpGaD
Etodolac—RXRA—Biological oxidations—GSTP1—bone cancer	0.000198	0.00258	CbGpPWpGaD
Etodolac—Visual impairment—Doxorubicin—bone cancer	0.000198	0.00152	CcSEcCtD
Etodolac—UGT1A9—NRF2 pathway—GSTP1—bone cancer	0.000196	0.00256	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—TGFBR2—bone cancer	0.000196	0.00256	CbGpPWpGaD
Etodolac—Alopecia—Epirubicin—bone cancer	0.000196	0.0015	CcSEcCtD
Etodolac—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000196	0.00255	CbGpPWpGaD
Etodolac—Vomiting—Cisplatin—bone cancer	0.000195	0.0015	CcSEcCtD
Etodolac—Vision blurred—Methotrexate—bone cancer	0.000194	0.00149	CcSEcCtD
Etodolac—Erythema multiforme—Doxorubicin—bone cancer	0.000194	0.00149	CcSEcCtD
Etodolac—Rash—Cisplatin—bone cancer	0.000193	0.00148	CcSEcCtD
Etodolac—Dermatitis—Cisplatin—bone cancer	0.000193	0.00148	CcSEcCtD
Etodolac—Ill-defined disorder—Methotrexate—bone cancer	0.000191	0.00147	CcSEcCtD
Etodolac—Tinnitus—Doxorubicin—bone cancer	0.000191	0.00147	CcSEcCtD
Etodolac—Anaemia—Methotrexate—bone cancer	0.00019	0.00146	CcSEcCtD
Etodolac—Flushing—Doxorubicin—bone cancer	0.00019	0.00146	CcSEcCtD
Etodolac—Flatulence—Epirubicin—bone cancer	0.00019	0.00146	CcSEcCtD
Etodolac—Tension—Epirubicin—bone cancer	0.000189	0.00145	CcSEcCtD
Etodolac—Dysgeusia—Epirubicin—bone cancer	0.000189	0.00145	CcSEcCtD
Etodolac—Nervousness—Epirubicin—bone cancer	0.000187	0.00144	CcSEcCtD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000186	0.00243	CbGpPWpGaD
Etodolac—Malaise—Methotrexate—bone cancer	0.000186	0.00143	CcSEcCtD
Etodolac—Vertigo—Methotrexate—bone cancer	0.000185	0.00142	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—bone cancer	0.000184	0.00142	CcSEcCtD
Etodolac—Chills—Doxorubicin—bone cancer	0.000184	0.00141	CcSEcCtD
Etodolac—Arrhythmia—Doxorubicin—bone cancer	0.000183	0.00141	CcSEcCtD
Etodolac—Nausea—Cisplatin—bone cancer	0.000182	0.0014	CcSEcCtD
Etodolac—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000182	0.00237	CbGpPWpGaD
Etodolac—Vision blurred—Epirubicin—bone cancer	0.000182	0.0014	CcSEcCtD
Etodolac—Alopecia—Doxorubicin—bone cancer	0.000181	0.00139	CcSEcCtD
Etodolac—RXRA—Generic Transcription Pathway—NR1I2—bone cancer	0.000181	0.00236	CbGpPWpGaD
Etodolac—Ill-defined disorder—Epirubicin—bone cancer	0.000179	0.00137	CcSEcCtD
Etodolac—Convulsion—Methotrexate—bone cancer	0.000179	0.00137	CcSEcCtD
Etodolac—Anaemia—Epirubicin—bone cancer	0.000178	0.00137	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000178	0.00232	CbGpPWpGaD
Etodolac—RXRA—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000177	0.00231	CbGpPWpGaD
Etodolac—Flatulence—Doxorubicin—bone cancer	0.000176	0.00135	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—bone cancer	0.000175	0.00135	CcSEcCtD
Etodolac—Myalgia—Methotrexate—bone cancer	0.000175	0.00135	CcSEcCtD
Etodolac—Tension—Doxorubicin—bone cancer	0.000175	0.00135	CcSEcCtD
Etodolac—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000175	0.00228	CbGpPWpGaD
Etodolac—Dysgeusia—Doxorubicin—bone cancer	0.000175	0.00134	CcSEcCtD
Etodolac—Malaise—Epirubicin—bone cancer	0.000174	0.00134	CcSEcCtD
Etodolac—Discomfort—Methotrexate—bone cancer	0.000173	0.00133	CcSEcCtD
Etodolac—Nervousness—Doxorubicin—bone cancer	0.000173	0.00133	CcSEcCtD
Etodolac—Vertigo—Epirubicin—bone cancer	0.000173	0.00133	CcSEcCtD
Etodolac—Syncope—Epirubicin—bone cancer	0.000173	0.00133	CcSEcCtD
Etodolac—Leukopenia—Epirubicin—bone cancer	0.000173	0.00133	CcSEcCtD
Etodolac—UGT1A9—Biological oxidations—GSTP1—bone cancer	0.000172	0.00225	CbGpPWpGaD
Etodolac—Palpitations—Epirubicin—bone cancer	0.00017	0.00131	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00017	0.00222	CbGpPWpGaD
Etodolac—UGT1A9—Metapathway biotransformation—GSTP1—bone cancer	0.00017	0.00222	CbGpPWpGaD
Etodolac—Confusional state—Methotrexate—bone cancer	0.00017	0.0013	CcSEcCtD
Etodolac—Loss of consciousness—Epirubicin—bone cancer	0.000169	0.0013	CcSEcCtD
Etodolac—Anaphylactic shock—Methotrexate—bone cancer	0.000168	0.00129	CcSEcCtD
Etodolac—Vision blurred—Doxorubicin—bone cancer	0.000168	0.00129	CcSEcCtD
Etodolac—Convulsion—Epirubicin—bone cancer	0.000167	0.00128	CcSEcCtD
Etodolac—Infection—Methotrexate—bone cancer	0.000167	0.00128	CcSEcCtD
Etodolac—Hypertension—Epirubicin—bone cancer	0.000166	0.00128	CcSEcCtD
Etodolac—Ill-defined disorder—Doxorubicin—bone cancer	0.000166	0.00127	CcSEcCtD
Etodolac—Anaemia—Doxorubicin—bone cancer	0.000165	0.00127	CcSEcCtD
Etodolac—Thrombocytopenia—Methotrexate—bone cancer	0.000165	0.00126	CcSEcCtD
Etodolac—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000164	0.00214	CbGpPWpGaD
Etodolac—Arthralgia—Epirubicin—bone cancer	0.000164	0.00126	CcSEcCtD
Etodolac—Myalgia—Epirubicin—bone cancer	0.000164	0.00126	CcSEcCtD
Etodolac—Anxiety—Epirubicin—bone cancer	0.000164	0.00126	CcSEcCtD
Etodolac—Hyperhidrosis—Methotrexate—bone cancer	0.000163	0.00125	CcSEcCtD
Etodolac—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000163	0.00212	CbGpPWpGaD
Etodolac—Discomfort—Epirubicin—bone cancer	0.000162	0.00125	CcSEcCtD
Etodolac—Malaise—Doxorubicin—bone cancer	0.000161	0.00124	CcSEcCtD
Etodolac—Dry mouth—Epirubicin—bone cancer	0.000161	0.00123	CcSEcCtD
Etodolac—Vertigo—Doxorubicin—bone cancer	0.00016	0.00123	CcSEcCtD
Etodolac—Anorexia—Methotrexate—bone cancer	0.00016	0.00123	CcSEcCtD
Etodolac—Syncope—Doxorubicin—bone cancer	0.00016	0.00123	CcSEcCtD
Etodolac—Leukopenia—Doxorubicin—bone cancer	0.00016	0.00123	CcSEcCtD
Etodolac—Confusional state—Epirubicin—bone cancer	0.000159	0.00122	CcSEcCtD
Etodolac—Palpitations—Doxorubicin—bone cancer	0.000158	0.00121	CcSEcCtD
Etodolac—Anaphylactic shock—Epirubicin—bone cancer	0.000157	0.00121	CcSEcCtD
Etodolac—Oedema—Epirubicin—bone cancer	0.000157	0.00121	CcSEcCtD
Etodolac—Hypotension—Methotrexate—bone cancer	0.000157	0.00121	CcSEcCtD
Etodolac—Loss of consciousness—Doxorubicin—bone cancer	0.000157	0.0012	CcSEcCtD
Etodolac—Infection—Epirubicin—bone cancer	0.000156	0.0012	CcSEcCtD
Etodolac—RXRA—Adipogenesis—RB1—bone cancer	0.000156	0.00203	CbGpPWpGaD
Etodolac—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000156	0.00203	CbGpPWpGaD
Etodolac—Shock—Epirubicin—bone cancer	0.000155	0.00119	CcSEcCtD
Etodolac—Convulsion—Doxorubicin—bone cancer	0.000155	0.00119	CcSEcCtD
Etodolac—Thrombocytopenia—Epirubicin—bone cancer	0.000154	0.00118	CcSEcCtD
Etodolac—Hypertension—Doxorubicin—bone cancer	0.000154	0.00118	CcSEcCtD
Etodolac—Tachycardia—Epirubicin—bone cancer	0.000154	0.00118	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000153	0.00118	CcSEcCtD
Etodolac—RXRA—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000153	0.002	CbGpPWpGaD
Etodolac—Hyperhidrosis—Epirubicin—bone cancer	0.000152	0.00117	CcSEcCtD
Etodolac—Insomnia—Methotrexate—bone cancer	0.000152	0.00117	CcSEcCtD
Etodolac—Arthralgia—Doxorubicin—bone cancer	0.000152	0.00117	CcSEcCtD
Etodolac—Myalgia—Doxorubicin—bone cancer	0.000152	0.00117	CcSEcCtD
Etodolac—Anxiety—Doxorubicin—bone cancer	0.000151	0.00116	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—bone cancer	0.000151	0.00116	CcSEcCtD
Etodolac—Discomfort—Doxorubicin—bone cancer	0.00015	0.00115	CcSEcCtD
Etodolac—Anorexia—Epirubicin—bone cancer	0.00015	0.00115	CcSEcCtD
Etodolac—Dyspnoea—Methotrexate—bone cancer	0.00015	0.00115	CcSEcCtD
Etodolac—Somnolence—Methotrexate—bone cancer	0.000149	0.00115	CcSEcCtD
Etodolac—UGT2B7—Metabolism—NDUFA12—bone cancer	0.000149	0.00194	CbGpPWpGaD
Etodolac—Dry mouth—Doxorubicin—bone cancer	0.000149	0.00114	CcSEcCtD
Etodolac—Dyspepsia—Methotrexate—bone cancer	0.000148	0.00114	CcSEcCtD
Etodolac—Hypotension—Epirubicin—bone cancer	0.000147	0.00113	CcSEcCtD
Etodolac—Confusional state—Doxorubicin—bone cancer	0.000147	0.00113	CcSEcCtD
Etodolac—Decreased appetite—Methotrexate—bone cancer	0.000146	0.00112	CcSEcCtD
Etodolac—Anaphylactic shock—Doxorubicin—bone cancer	0.000146	0.00112	CcSEcCtD
Etodolac—Oedema—Doxorubicin—bone cancer	0.000146	0.00112	CcSEcCtD
Etodolac—Fatigue—Methotrexate—bone cancer	0.000145	0.00111	CcSEcCtD
Etodolac—UGT1A3—Metabolism—NT5C3A—bone cancer	0.000145	0.00189	CbGpPWpGaD
Etodolac—Infection—Doxorubicin—bone cancer	0.000145	0.00111	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000145	0.00189	CbGpPWpGaD
Etodolac—Pain—Methotrexate—bone cancer	0.000144	0.0011	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000143	0.0011	CcSEcCtD
Etodolac—Shock—Doxorubicin—bone cancer	0.000143	0.0011	CcSEcCtD
Etodolac—Thrombocytopenia—Doxorubicin—bone cancer	0.000143	0.0011	CcSEcCtD
Etodolac—Insomnia—Epirubicin—bone cancer	0.000142	0.00109	CcSEcCtD
Etodolac—Tachycardia—Doxorubicin—bone cancer	0.000142	0.00109	CcSEcCtD
Etodolac—Paraesthesia—Epirubicin—bone cancer	0.000141	0.00109	CcSEcCtD
Etodolac—Hyperhidrosis—Doxorubicin—bone cancer	0.000141	0.00108	CcSEcCtD
Etodolac—PTGS1—Biological oxidations—GSTP1—bone cancer	0.00014	0.00183	CbGpPWpGaD
Etodolac—Dyspnoea—Epirubicin—bone cancer	0.00014	0.00108	CcSEcCtD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.00014	0.00182	CbGpPWpGaD
Etodolac—Somnolence—Epirubicin—bone cancer	0.00014	0.00107	CcSEcCtD
Etodolac—Anorexia—Doxorubicin—bone cancer	0.000139	0.00107	CcSEcCtD
Etodolac—RXRA—Metabolism—NDUFA12—bone cancer	0.000139	0.00181	CbGpPWpGaD
Etodolac—Feeling abnormal—Methotrexate—bone cancer	0.000139	0.00106	CcSEcCtD
Etodolac—Dyspepsia—Epirubicin—bone cancer	0.000139	0.00106	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—bone cancer	0.000138	0.00106	CcSEcCtD
Etodolac—Decreased appetite—Epirubicin—bone cancer	0.000137	0.00105	CcSEcCtD
Etodolac—Hypotension—Doxorubicin—bone cancer	0.000136	0.00105	CcSEcCtD
Etodolac—Fatigue—Epirubicin—bone cancer	0.000136	0.00104	CcSEcCtD
Etodolac—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000135	0.00176	CbGpPWpGaD
Etodolac—Constipation—Epirubicin—bone cancer	0.000135	0.00103	CcSEcCtD
Etodolac—Pain—Epirubicin—bone cancer	0.000135	0.00103	CcSEcCtD
Etodolac—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000134	0.00175	CbGpPWpGaD
Etodolac—Urticaria—Methotrexate—bone cancer	0.000134	0.00103	CcSEcCtD
Etodolac—Body temperature increased—Methotrexate—bone cancer	0.000133	0.00102	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—bone cancer	0.000133	0.00102	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000133	0.00102	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000132	0.00172	CbGpPWpGaD
Etodolac—Insomnia—Doxorubicin—bone cancer	0.000132	0.00101	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000132	0.00172	CbGpPWpGaD
Etodolac—Paraesthesia—Doxorubicin—bone cancer	0.000131	0.001	CcSEcCtD
Etodolac—Dyspnoea—Doxorubicin—bone cancer	0.00013	0.000997	CcSEcCtD
Etodolac—Feeling abnormal—Epirubicin—bone cancer	0.00013	0.000996	CcSEcCtD
Etodolac—Somnolence—Doxorubicin—bone cancer	0.000129	0.000995	CcSEcCtD
Etodolac—Gastrointestinal pain—Epirubicin—bone cancer	0.000129	0.000989	CcSEcCtD
Etodolac—Dyspepsia—Doxorubicin—bone cancer	0.000128	0.000985	CcSEcCtD
Etodolac—Decreased appetite—Doxorubicin—bone cancer	0.000127	0.000973	CcSEcCtD
Etodolac—RXRA—Gene Expression—FUS—bone cancer	0.000126	0.00164	CbGpPWpGaD
Etodolac—Fatigue—Doxorubicin—bone cancer	0.000126	0.000965	CcSEcCtD
Etodolac—Urticaria—Epirubicin—bone cancer	0.000125	0.000961	CcSEcCtD
Etodolac—Pain—Doxorubicin—bone cancer	0.000125	0.000957	CcSEcCtD
Etodolac—Constipation—Doxorubicin—bone cancer	0.000125	0.000957	CcSEcCtD
Etodolac—Abdominal pain—Epirubicin—bone cancer	0.000124	0.000956	CcSEcCtD
Etodolac—Body temperature increased—Epirubicin—bone cancer	0.000124	0.000956	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000124	0.00162	CbGpPWpGaD
Etodolac—Hypersensitivity—Methotrexate—bone cancer	0.000124	0.000952	CcSEcCtD
Etodolac—UGT2B7—Metabolism—NT5C3A—bone cancer	0.000123	0.00161	CbGpPWpGaD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000123	0.0016	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NDUFA12—bone cancer	0.000121	0.00157	CbGpPWpGaD
Etodolac—Asthenia—Methotrexate—bone cancer	0.000121	0.000927	CcSEcCtD
Etodolac—Feeling abnormal—Doxorubicin—bone cancer	0.00012	0.000922	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00012	0.00156	CbGpPWpGaD
Etodolac—Gastrointestinal pain—Doxorubicin—bone cancer	0.000119	0.000915	CcSEcCtD
Etodolac—Pruritus—Methotrexate—bone cancer	0.000119	0.000914	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000118	0.00154	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000118	0.00153	CbGpPWpGaD
Etodolac—Hypersensitivity—Epirubicin—bone cancer	0.000116	0.000891	CcSEcCtD
Etodolac—Urticaria—Doxorubicin—bone cancer	0.000116	0.000889	CcSEcCtD
Etodolac—Body temperature increased—Doxorubicin—bone cancer	0.000115	0.000884	CcSEcCtD
Etodolac—Abdominal pain—Doxorubicin—bone cancer	0.000115	0.000884	CcSEcCtD
Etodolac—Diarrhoea—Methotrexate—bone cancer	0.000115	0.000884	CcSEcCtD
Etodolac—RXRA—Metabolism—NT5C3A—bone cancer	0.000115	0.0015	CbGpPWpGaD
Etodolac—Asthenia—Epirubicin—bone cancer	0.000113	0.000867	CcSEcCtD
Etodolac—Pruritus—Epirubicin—bone cancer	0.000111	0.000855	CcSEcCtD
Etodolac—Dizziness—Methotrexate—bone cancer	0.000111	0.000854	CcSEcCtD
Etodolac—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.000109	0.00142	CbGpPWpGaD
Etodolac—Diarrhoea—Epirubicin—bone cancer	0.000108	0.000827	CcSEcCtD
Etodolac—Hypersensitivity—Doxorubicin—bone cancer	0.000107	0.000824	CcSEcCtD
Etodolac—Vomiting—Methotrexate—bone cancer	0.000107	0.000821	CcSEcCtD
Etodolac—Rash—Methotrexate—bone cancer	0.000106	0.000815	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—bone cancer	0.000106	0.000814	CcSEcCtD
Etodolac—Headache—Methotrexate—bone cancer	0.000105	0.000809	CcSEcCtD
Etodolac—Asthenia—Doxorubicin—bone cancer	0.000104	0.000803	CcSEcCtD
Etodolac—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000104	0.00136	CbGpPWpGaD
Etodolac—Dizziness—Epirubicin—bone cancer	0.000104	0.0008	CcSEcCtD
Etodolac—Pruritus—Doxorubicin—bone cancer	0.000103	0.000792	CcSEcCtD
Etodolac—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000103	0.00134	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.0001	0.00131	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—NT5C3A—bone cancer	0.0001	0.0013	CbGpPWpGaD
Etodolac—Vomiting—Epirubicin—bone cancer	0.0001	0.000769	CcSEcCtD
Etodolac—Nausea—Methotrexate—bone cancer	9.99e-05	0.000767	CcSEcCtD
Etodolac—Diarrhoea—Doxorubicin—bone cancer	9.96e-05	0.000765	CcSEcCtD
Etodolac—Rash—Epirubicin—bone cancer	9.92e-05	0.000762	CcSEcCtD
Etodolac—Dermatitis—Epirubicin—bone cancer	9.91e-05	0.000762	CcSEcCtD
Etodolac—Headache—Epirubicin—bone cancer	9.86e-05	0.000757	CcSEcCtD
Etodolac—PTGS1—Metabolism—NDUFA12—bone cancer	9.84e-05	0.00128	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.77e-05	0.00127	CbGpPWpGaD
Etodolac—Dizziness—Doxorubicin—bone cancer	9.63e-05	0.00074	CcSEcCtD
Etodolac—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	9.52e-05	0.00124	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—RB1—bone cancer	9.5e-05	0.00124	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	9.42e-05	0.00123	CbGpPWpGaD
Etodolac—Nausea—Epirubicin—bone cancer	9.35e-05	0.000718	CcSEcCtD
Etodolac—Vomiting—Doxorubicin—bone cancer	9.26e-05	0.000711	CcSEcCtD
Etodolac—Rash—Doxorubicin—bone cancer	9.18e-05	0.000705	CcSEcCtD
Etodolac—Dermatitis—Doxorubicin—bone cancer	9.17e-05	0.000705	CcSEcCtD
Etodolac—Headache—Doxorubicin—bone cancer	9.12e-05	0.000701	CcSEcCtD
Etodolac—RXRA—Gene Expression—NR1I2—bone cancer	8.71e-05	0.00114	CbGpPWpGaD
Etodolac—Nausea—Doxorubicin—bone cancer	8.65e-05	0.000665	CcSEcCtD
Etodolac—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.63e-05	0.00113	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	8.63e-05	0.00113	CbGpPWpGaD
Etodolac—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.51e-05	0.00111	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	8.5e-05	0.00111	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—NT5C3A—bone cancer	8.16e-05	0.00106	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.09e-05	0.00105	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	7.99e-05	0.00104	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NDUFA12—bone cancer	7.81e-05	0.00102	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	7.43e-05	0.000969	CbGpPWpGaD
Etodolac—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.38e-05	0.000963	CbGpPWpGaD
Etodolac—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.28e-05	0.000949	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.98e-05	0.00091	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—MMP9—bone cancer	6.85e-05	0.000893	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.68e-05	0.000871	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—NT5C3A—bone cancer	6.48e-05	0.000844	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—EIF2S1—bone cancer	6.43e-05	0.000838	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—ENO2—bone cancer	6.34e-05	0.000827	CbGpPWpGaD
Etodolac—ALB—Metabolism—NDUFA12—bone cancer	6.32e-05	0.000824	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—CDK4—bone cancer	6.16e-05	0.000804	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MET—bone cancer	6.16e-05	0.000804	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—TP53—bone cancer	5.98e-05	0.00078	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—DHFR—bone cancer	5.88e-05	0.000767	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.61e-05	0.000731	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—EZH2—bone cancer	5.59e-05	0.000728	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—EGFR—bone cancer	5.54e-05	0.000722	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.51e-05	0.000718	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GNA11—bone cancer	5.5e-05	0.000717	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—ENO2—bone cancer	5.39e-05	0.000703	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SPARC—bone cancer	5.37e-05	0.0007	CbGpPWpGaD
Etodolac—ALB—Metabolism—NT5C3A—bone cancer	5.24e-05	0.000683	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NDUFA12—bone cancer	5.17e-05	0.000675	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MMP2—bone cancer	5.14e-05	0.00067	CbGpPWpGaD
Etodolac—RXRA—Metabolism—ENO2—bone cancer	5.03e-05	0.000656	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—DHFR—bone cancer	5e-05	0.000652	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CYP3A4—bone cancer	4.99e-05	0.00065	CbGpPWpGaD
Etodolac—ALB—Hemostasis—GNA11—bone cancer	4.91e-05	0.00064	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.79e-05	0.000624	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GNA11—bone cancer	4.68e-05	0.00061	CbGpPWpGaD
Etodolac—RXRA—Metabolism—DHFR—bone cancer	4.67e-05	0.000609	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—bone cancer	4.65e-05	0.000606	CbGpPWpGaD
Etodolac—ALB—Hemostasis—IL3—bone cancer	4.45e-05	0.00058	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—ENO2—bone cancer	4.38e-05	0.000571	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GNA11—bone cancer	4.36e-05	0.000569	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NT5C3A—bone cancer	4.29e-05	0.000559	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—GSTP1—bone cancer	4.26e-05	0.000556	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CYP3A4—bone cancer	4.24e-05	0.000553	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—DHFR—bone cancer	4.07e-05	0.00053	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CYP3A4—bone cancer	3.95e-05	0.000516	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.93e-05	0.000513	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—MMP9—bone cancer	3.86e-05	0.000504	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GNA11—bone cancer	3.8e-05	0.000495	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.77e-05	0.000491	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—GSTP1—bone cancer	3.63e-05	0.000473	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—ENO2—bone cancer	3.57e-05	0.000466	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CYP3A4—bone cancer	3.45e-05	0.000449	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.43e-05	0.000447	CbGpPWpGaD
Etodolac—PTGS2—Disease—ENO2—bone cancer	3.39e-05	0.000442	CbGpPWpGaD
Etodolac—RXRA—Metabolism—GSTP1—bone cancer	3.38e-05	0.000441	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—DHFR—bone cancer	3.31e-05	0.000432	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.16e-05	0.000412	CbGpPWpGaD
Etodolac—PTGS2—Disease—DHFR—bone cancer	3.14e-05	0.00041	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—EGFR—bone cancer	3.12e-05	0.000407	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GNA11—bone cancer	3.1e-05	0.000404	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—GSTP1—bone cancer	2.95e-05	0.000384	CbGpPWpGaD
Etodolac—ALB—Hemostasis—PLAU—bone cancer	2.92e-05	0.00038	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—ENO2—bone cancer	2.84e-05	0.00037	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CYP3A4—bone cancer	2.81e-05	0.000366	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.79e-05	0.000364	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—DHFR—bone cancer	2.63e-05	0.000343	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GNA11—bone cancer	2.46e-05	0.000321	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—GSTP1—bone cancer	2.4e-05	0.000313	CbGpPWpGaD
Etodolac—ALB—Metabolism—ENO2—bone cancer	2.29e-05	0.000299	CbGpPWpGaD
Etodolac—PTGS2—Disease—TGFBR2—bone cancer	2.28e-05	0.000297	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CYP3A4—bone cancer	2.23e-05	0.000291	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PTGS2—bone cancer	2.21e-05	0.000288	CbGpPWpGaD
Etodolac—ALB—Metabolism—DHFR—bone cancer	2.13e-05	0.000278	CbGpPWpGaD
Etodolac—ALB—Metabolism—GNA11—bone cancer	1.99e-05	0.000259	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—GSTP1—bone cancer	1.91e-05	0.000249	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PTGS2—bone cancer	1.88e-05	0.000245	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—ENO2—bone cancer	1.88e-05	0.000245	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP3A4—bone cancer	1.8e-05	0.000235	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.79e-05	0.000234	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PTGS2—bone cancer	1.75e-05	0.000228	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—DHFR—bone cancer	1.74e-05	0.000227	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GNA11—bone cancer	1.63e-05	0.000212	CbGpPWpGaD
Etodolac—PTGS2—Disease—KIT—bone cancer	1.55e-05	0.000203	CbGpPWpGaD
Etodolac—ALB—Metabolism—GSTP1—bone cancer	1.54e-05	0.000201	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PTGS2—bone cancer	1.53e-05	0.000199	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP3A4—bone cancer	1.48e-05	0.000192	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.47e-05	0.000192	CbGpPWpGaD
Etodolac—PTGS2—Disease—BRAF—bone cancer	1.46e-05	0.00019	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—GSTP1—bone cancer	1.26e-05	0.000165	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PTGS2—bone cancer	1.24e-05	0.000162	CbGpPWpGaD
Etodolac—PTGS2—Disease—MDM2—bone cancer	1.22e-05	0.00016	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—bone cancer	1.17e-05	0.000153	CbGpPWpGaD
Etodolac—PTGS2—Disease—EGFR—bone cancer	8.36e-06	0.000109	CbGpPWpGaD
Etodolac—ALB—Metabolism—PTGS2—bone cancer	7.99e-06	0.000104	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PTGS2—bone cancer	6.54e-06	8.53e-05	CbGpPWpGaD
